Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth

Bahar-Fuchs, 2013, Prediction of amyloid-beta pathology in amnestic mild cognitive impairment with neuropsychological tests, J. Alzheimers Dis., 33, 451, 10.3233/JAD-2012-121315 Barthel, 2011, Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study, Lancet Neurol., 10, 424, 10.1016/S1474-4422(11)70077-1 Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med., 367, 795, 10.1056/NEJMoa1202753 Castellano, 2011, Human apoE isoforms differentially regulate brain amyloid-β peptide clearance, Sci. Transl. Med., 3, 89ra57, 10.1126/scitranslmed.3002156 Chetelat, 2012, Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease, Neurodegener Dis, 10, 141, 10.1159/000334295 Clark, 2011, Use of florbetapir-PET for imaging beta-amyloid pathology, JAMA, 305, 275, 10.1001/jama.2010.2008 Doraiswamy, 2012, Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study, Neurology, 79, 1636, 10.1212/WNL.0b013e3182661f74 Drzezga, 2009, Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease, Neurology, 72, 1487, 10.1212/WNL.0b013e3181a2e8d0 Fleisher, 2011, Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease, Arch. Neurol., 68, 1404, 10.1001/archneurol.2011.150 Fleisher, 2012, Florbetapir PET analyses of amyloid depositon in the presenelin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study, Lancet Neurol., 11, 1057, 10.1016/S1474-4422(12)70227-2 Fleisher, 2013, Apolipoprotien E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease, Neurobiol. Aging, 34, 1, 10.1016/j.neurobiolaging.2012.04.017 Frisoni, 2012, Alzheimer disease: biomarker trajectories across stages of Alzheimer disease, Nat. Rev. Neurol., 8, 299, 10.1038/nrneurol.2012.81 Grimmer, 2010, Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease, Biol. Psychiatry, 68, 879, 10.1016/j.biopsych.2010.05.013 Huang, 2002, Cingulate cortex hypoperfusion predicts Alzheimer's disease in MCI patients, BMC Neurol., 2, 9, 10.1186/1471-2377-2-9 Huang, 2012, Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system, Arch. Neurol., 69, 51, 10.1001/archneurol.2011.235 Jack, 2012, Shapes of the trajectories of 5 major biomarkers of Alzheimer disease, Arch. Neurol., 69, 856, 10.1001/archneurol.2011.3405 Kantarci, 2012, APOE modifies the association between abeta load and cognition in cognitively normal older adults, Neurology, 78, 232, 10.1212/WNL.0b013e31824365ab Landau, 2012, Amyloid deposition, hypometabolism, and longitudinal cognitive decline, Ann. Neurol., 72, 578, 10.1002/ana.23650 Mosconi, 2010, Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's, Proc. Natl. Acad. Sci. U. S. A., 107, 5949, 10.1073/pnas.0914141107 The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease, 1997, Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease, Neurobiol. Aging, 18, S1 Nordberg, 2010, The use of PET in Alzheimer disease, Nat. Rev. Neurol., 6, 78, 10.1038/nrneurol.2009.217 Pievani, 2011, Functional network disruption in the degenerative dementias, Lancet Neurol., 10, 829, 10.1016/S1474-4422(11)70158-2 Reiman, 2009, Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 106, 6820, 10.1073/pnas.0900345106 Selkoe, 2012, Preventing Alzheimer's disease, Science, 337, 1488, 10.1126/science.1228541 Small, 2009, Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia, Arch. Gen. Psychiatry, 66, 81, 10.1001/archgenpsychiatry.2008.516 Sojkova, 2011, Longitudinal patterns of beta-amyloid deposition in nondemented older adults, Arch. Neurol., 68, 644, 10.1001/archneurol.2011.77 Sperling, 2011, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup, Alzheimers Dement., 7, 280, 10.1016/j.jalz.2011.03.003 Sperling, 2013, Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals, Neurobiol. Aging, 34, 822, 10.1016/j.neurobiolaging.2012.06.014 Swaminathan, 2012, Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, Brain Imaging Behav., 6, 1, 10.1007/s11682-011-9136-1 Vlassenko, 2011, Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data, Ann. Neurol., 70, 857, 10.1002/ana.22608 Weiner, 2010, Alzheimer's disease neuroimaging initiative. Alzheimer's disease neuroimaging initiative: progress report and future plans, Alzheimers Dement., 6, 202, 10.1016/j.jalz.2010.03.007